AR057960A1 - Inhibidores de proteina quinasa biciclicos - Google Patents
Inhibidores de proteina quinasa biciclicosInfo
- Publication number
- AR057960A1 AR057960A1 ARP060105328A ARP060105328A AR057960A1 AR 057960 A1 AR057960 A1 AR 057960A1 AR P060105328 A ARP060105328 A AR P060105328A AR P060105328 A ARP060105328 A AR P060105328A AR 057960 A1 AR057960 A1 AR 057960A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkenyl
- alkynyl
- aryl
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
Inhiben enzimas proteína quinasa, y son utiles para el tratamiento y la prevencion de enfermedades hiperproliferativas, tales como cáncer, inflamacion, soriasis, alergia/asma, enfermedades y afecciones del sistema inmunitario, y enfermedades y afecciones del sistema nervioso central. Reivindicacion 1: Un compuesto de la formula (1) o una de sus sales aceptables para uso farmacéutico, donde: R1 es -OR4, -NR4R5, -C(=O)R4, -CO2R4, -CONR4R5, -NO2, -CN, -S(O)j1R4, -SO2NR4R5, -NR4C(=O)R5, - NR4C(=O)OR5, -NR4C(=O)NR5R5a, -NR4S(O)j1R5, -C(=S)OR4, -C(=O)SR4, -NR4C(=NR5)NR4aR5a, -NR4C(=NR5)OR4a, -NR4C(=NR5)SR4a, -OC(=O)OR5, -OC(=O)NR4R5, -OC(=O)SR4, -SC(=O)OR4, o -SC(=O)NR4R5; R2 y R3 son, de manera independiente, alquilo C0-10, cicloalquilo C3-10, bicicloalquilo C5-10, arilo, heteroarilo, aralquilo, heteroaralquilo, heterociclilo, heterobicicloalquilo C5-10 espiroalquilo o heteroespiroalquilo, donde cualquiera de estos está opcionalmente sustituido con uno o más sustituyentes independientes G1; X1 y X2 son, de modo independiente, N o -C-E1; X5 es N, -C-E1, o -N-(E1)aa; X3, X4, X6 y X7 son, de manera independiente, -N-(E1)aa o C; donde por lo menos uno de X3, X4, X5, X6 y X7 es -N-(E1)aa; Q1es halo, -CF3, - OCF3, -OR66, -NR66R77(R66a)j11, -C(=O)R66, -CO2R66, -CONR66R77, -NO2, -CN, -S(O)j11R66, -SO2NR66R77, -NR66C(=O)R77, -NR66C(=O)OR77, -NR66C(=O)NR77R66a, -NR66S(O)j11R77, -C(=S)OR66, -C(=O)SR66, -NR66C(=NR77)NR66aR77a, -NR66C(=NR77)OR66a, - NR66C(=NR77)SR66a, -OC(=O)OR66, -OC(=O)NR66R77, -OC(=O)SR66, -SC(=O)OR66, -SC(=O)NR66R77, alquilo C0-10, alquenilo C2-10, alquinilo C2-10, alcoxiC1-10-alquilo C1-10, alcoxiC1-10-alquenilo C2-10, alcoxiC1-10-alquinilo C2-10, alquiltioC1-10-alquilo C1- 10, alquiltioC1-10-alquenilo C2-10, alquiltioC1-10-alquinilo C2-10, cicloalquilo C3-8, cicloalquenilo C3-8, cicloalquiloC3-8-alquilo C1-10, cicloalqueniloC3-8-alquiloC1-10, cicloalquiloC3-8alquenilo C2-10, cicloalqueniloC3-8-alquenilo C2-10, cicloalquiloC3-8-alquinilo C2-10, cicloalquenilo C3-8-alquinilo C2-10, heterociclilo-alquilo C0-10, heterociclilo-alquenilo C2-10, heterociclilo-alquinilo C2-10, arilo-alquiloC0-10, arilo-alquenilo C2-10, arilo-alquinilo C2-10, hetarilo-alquilo C0- 10, hetarilo-alquenilo C2-10, o hetarilo-alquinilo C2-10, donde cualquiera de los cuales está opcionalmente sustituido con uno o más sustituyentes independientes G11; o Q1 es cualquiera de los compuestos 2 a 31, alcoxiC1-10-alquenilo C2-10, alcoxiC1- 10-alquinilo C2-10, alquiltioC1-10-alquilo C1-10, alquiltioC1-10-alquenilo C2-10, alquiltioC1-10-alquinilo C2-10, cicloalquilo C3-8, cicloalquenilo C3-8, cicloalquiloC3-8-alquilo C1-10, cicloalqueniloC3-8-alquiloC1-10, cicloalquiloC3-8alquenilo C2- 10, cicloalqueniloC3-8-alquenilo C2-10, cicloalquiloC3-8-alquinilo C2-10, cicloalquenilo C3-8-alquinilo C2-10, heterociclilo-alquilo C0-10, heterociclilo-alquenilo C2-10, heterociclilo-alquinilo C2-10, arilo-alquiloC0-10, arilo-alquenilo C2-10, arilo-alquinilo C2-10, hetarilo-alquilo C0-10, hetarilo-alquenilo C2-10, o hetarilo-alquinilo C2-10, donde cualquiera de los estos está opcionalmente sustituido con uno o más sustituyentes independientes halo, oxo, -CF3, -OCF3, -OR222, - NR222R333(R222a)j1a, -C(=O)R222, -CO2R222, -C(=O)NR222R333, -NO2, -CN, -S(=O)j1aR222, -SO2NR222R333, -NR222C(=O)R333, -NR222C(=O)OR333, -NR222C(=O)NR333R222a, -NR222S(O)j1aR333, -C(=S)OR222, -C(=O)SR222, -NR222C(=NR333)NR222aR333a, - NR222C(=NR333)OR222a, -NR222C(=NR333)SR222a, -OC(=O)OR222, -OC(=O)NR222R333, -OC(=O)SR222, -SC(=O)OR222, -SC(=O)NR222R333; R4, R4a, R5, R5a, R6, R6a, R7, R7a, R66, R66a, R77, R77a, R222, R222a, R333, y R333a son, de manera independiente, alquilo C0- 10, alquenilo C2-10, alquinilo C2-10, alcoxiC1-10-alquilo C1-10, alcoxiC1-10-alquenilo C2-10, alcoxiC1-10-alquinilo C2-10, alquiltioC1-10-alquilo C1-10, alquiltioC1-10-alquenilo C2-10, alquiltioC1-10-alquinilo C2-10, cicloalquilo C3-8, cicloalquenilo C3-8, cicloalquiloC3-8-alquilo C1-10, cicloalqueniloC3-8-alquiloC1-10, cicloalquiloC3-8alquenilo C2-10, cicloalqueniloC3-8-alquenilo C2-10, cicloalquiloC3-8-alquinilo C2-10, cicloalquenilo C3-8-alquinilo C2-10, heterociclilo-alquilo C0-10, heterociclilo-alquenilo C2-10, heterociclilo-alquinilo C2-10, arilo-alquiloC0-10, arilo-alquenilo C2-10, arilo-alquinilo C2-10, hetarilo-alquilo C0-10, hetarilo-alquenilo C2-10, o hetarilo-alquinilo C2-10, donde cualquiera de los estos está opcionalmente sustituido con uno o más sustituyentes independientes G111; o en el caso de -NR4R5, -NR5R5a, -NR4aR5a, -NR6R7(R6a)j1, -NR6aR7a, -NR7R6a, NR66R77(R66)j11, -NR77R66a, -NR66aR77a, -NR222R333(R222a)j1a, -NR333R222a, -NR222aR333a, - NR77bR87, -NR78R87 o -NR78R88, entonces R4 y R5, o R5 y R5a, o R4a y R5a, o R6 y R7, o R6a y R7a, o R7 y R6a, o R66 y R77, o R77 y R66a, o R66a y R77a, o R222 y R333, o R333 y R222a, o R222a y R333a, o R77b, y R87, o R78 y R87, o R78 y R88, respectivamente, en forma opcional, se toman junto con el átomo de N al cual están unidos, a fin de formar un anillo saturado o insaturado, de 3 a 10 miembros, donde dicho anillo está opcionalmente sustituido con uno o más sustituyentes independientes G1111, y donde dicho anillo comprende, en forma opcional, uno o más heteroátomos diferentes de N, a los cuales R4 y R5, o R5 y R5a, o R4a y R5a, o R6 y R7, o R6a y R7a, o R7 y R6a, o R66 y R77, o R77 y R66a, o R66a y R77a, o R222 y R333, o R333 y R222a, o R222a y R333a, o R77b, y R87, o R78 y R87, o R78 y R88 están unidos, G111 y G1111 son, de manera independiente alquilo C0-10, alquenilo C2-10, alquinilo C2-10, alcoxiC1-10-alquilo C1-10, alcoxiC1-10-alquenilo C2-10, alcoxiC1- 10-alquinilo C2-10, alquiltioC1-10-alquilo C1-10, alquiltioC1-10-alquenilo C2-10, alquiltioC1-10-alquinilo C2-10, cicloalquilo C3-8, cicloalquenilo C3-8, cicloalquiloC3-8-alquilo C1-10, cicloalqueniloC3-8-alquiloC1-10, cicloalquiloC3-8alquenilo C2- 10, cicloalqueniloC3-8-alquenilo C2-10, cicloalquiloC3-8-alquinilo C2-10, cicloalquenilo C3-8-alquinilo C2-10, heterociclilo-alquilo C0-10, heterociclilo-alquenilo C2-10, heterociclilo-alquinilo C2-10, arilo-alquiloC0-10, arilo-alquenilo C2-10, arilo-alquinilo C2-10, hetarilo-alquilo C0-10, hetarilo-alquenilo C2-10, o hetarilo-alquinilo C2-10, donde cualquiera de los estos está opcionalmente sustituido con uno o más sustituyentes independientes halo, -CF3, -OCF3, -OR77b, -NR77bR87, - C(O)R77b, -CO2R77b, -CO2R77b, -CONR77bR87, -NO2, -CN, -S(O)j5a1R77b, -SO2NR77bR87, -NR77bC(=O)R87, -NR77bC(=O)OR87, -NR77bC(=O)NR78R87, -NR77bS(O)j5aR87, -C(=S)OR77b, -C(=O)SR77b, -NR77bC(=NR87)NR78R88, -NR77bC(=NR87)OR78, -NR77bC(=NR87)SR78, - OC(=O)OR77b, -OC(=O)NR77bR87, -OC(=O)SR77b, -SC(=O)OR77b, -P(O)OR77bOR87, o -SC(=O)NR77bR87; R77b, R87 y R88 son, de manera independiente alquilo C0-10, alquenilo C2-10, alquinilo C2-10, alcoxiC1-10-alquilo C1-10, alcoxiC1-10-alquenilo C2-10, alcoxiC1-10-alquinilo C2-10, alquiltioC1-10-alquilo C1-10, alquiltioC1-10-alquenilo C2-10, alquiltioC1-10-alquinilo C2-10, cicloalquilo C3-8, cicloalquenilo C3-8, cicloalquiloC3-8-alquilo C1-10, cicloalqueniloC3-8-alquiloC1-10, cicloalquiloC3- 8alquenilo C2-10, cicloalqueniloC3-8-alquenilo C2-10, cicloalquiloC3-8-alquinilo C2-10, cicloalquenilo C3-8-alquinilo C2-10, heterociclilo-alquilo C0-10, heterociclilo-alquenilo C2-10, heterociclilo-alquinilo C2-10, alquilcarbonilo C1-10, alquenilcarbonilo C2-10, alquinilcarbonilo C2-10, alcoxicarbonilo C1-10, alcoxicarboniloC1-10alquilo C1-10, monoalquilaminocarbonilo C1-6, dialquilaminocarbonilo C1-6, mono(aril)aminocarbonilo, di(aril)aminocarbonilo, o alquiloC1- 10(aril)aminocarbonilo, donde cualquiera de estos está opcionalmente sustituido con uno o más sustituyentes independientes halo, ciano, hidroxi, nitro, alcoxi C1-10, -SO2N(alquilo C0-4)(alquilo C0-4), o -N(alquilo C0-4)(alquilo C0-4); o R77b, R87 y R88 son, de manera independiente, aril-alquiloC0-10, aril-alquenilo C2-10, aril-alquinilo C2-10, hetaril-alquilo C0-10, hetaril-alquenilo C2-10, hetaril-alquinilo C2-10, mono(alquilo C1-6)aminoalquilo C1-6, di(alquilo C1-6)aminoalquilo C1-6, mono(aril)aminoalquilo C1-6, di(aril)aminoalquilo C1-6 o -N(alquilo C1-6)-alquilo C1-6-arilo, donde cualquiera de estos puede estar opcionalmente sustituido con uno o más sustituyentes independientes halo, ciano, nitro, -O(alquilo C0-4), alquilo C1- 10, alquenilo C2-10, alquinilo C2-10, haloalquilo C1-10, haloalquenilo C2-10, haloalquinilo C2-10, -COOH, alcoxicarbonilo C1-4, -CON(alquilo C0-4)(alquilo C0-10), -SO2N(alquilo C0-4)(alquilo C0-4) o -N(alquilo C0-4)(alquilo C0-4), j1, j1a, j11 y j5a representan, de manera independiente, 0, 1 o 2; y aa es 0 o 1.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74158805P | 2005-12-02 | 2005-12-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR057960A1 true AR057960A1 (es) | 2007-12-26 |
Family
ID=37969677
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060105328A AR057960A1 (es) | 2005-12-02 | 2006-12-01 | Inhibidores de proteina quinasa biciclicos |
Country Status (6)
Country | Link |
---|---|
US (1) | US7648987B2 (es) |
EP (1) | EP1957496B1 (es) |
AR (1) | AR057960A1 (es) |
ES (1) | ES2395835T3 (es) |
TW (1) | TW200730528A (es) |
WO (1) | WO2007064993A2 (es) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1740591E (pt) * | 2004-04-02 | 2009-09-24 | Osi Pharm Inc | Inibidores da proteína quinase heterobicíclicos em substituição de anel bicíclico 6,6 |
JP5335432B2 (ja) * | 2005-11-17 | 2013-11-06 | オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー | 縮合2環系mTOR阻害剤 |
US8575164B2 (en) * | 2005-12-19 | 2013-11-05 | OSI Pharmaceuticals, LLC | Combination cancer therapy |
TW200738725A (en) * | 2006-01-25 | 2007-10-16 | Osi Pharm Inc | Unsaturated mTOR inhibitors |
US8124759B2 (en) | 2007-05-09 | 2012-02-28 | Abbott Laboratories | Inhibitors of protein kinases |
WO2008141140A1 (en) * | 2007-05-09 | 2008-11-20 | Abbott Laboratories | Condensed heterocyclic compounds as inhibitors of protein kinases |
MX2009012079A (es) * | 2007-05-09 | 2009-11-19 | Abbott Lab | Compuestos heterociclicos condensados como inhibidores de proteina cinasas. |
US20110160232A1 (en) | 2007-10-04 | 2011-06-30 | Pingda Ren | Certain chemical entities and therapeutic uses thereof |
WO2009091939A1 (en) * | 2008-01-18 | 2009-07-23 | Osi Pharmaceuticals, Inc. | Imidazopyrazinol derivatives for the treatment of cancers |
US8993580B2 (en) * | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
EP2252293B1 (en) * | 2008-03-14 | 2018-06-27 | Intellikine, LLC | Kinase inhibitors and methods of use |
US20100048912A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
EA018144B1 (ru) * | 2008-03-19 | 2013-05-30 | Оси Фармасьютикалз, Инк. | СОЛЕВЫЕ ФОРМЫ ИНГИБИТОРА mTOR |
EP2278966B1 (en) | 2008-03-21 | 2019-10-09 | The University of Chicago | Treatment with opioid antagonists and mtor inhibitors |
ES2396613T3 (es) * | 2008-05-19 | 2013-02-22 | OSI Pharmaceuticals, LLC | Imidazopirazinas e imidazotriazinas sustituidas |
CA2730106A1 (en) | 2008-07-08 | 2010-01-14 | Intellikine, Inc. | Kinase inhibitors and methods of use |
WO2010050445A1 (ja) * | 2008-10-27 | 2010-05-06 | 武田薬品工業株式会社 | 二環性化合物 |
US8476431B2 (en) * | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
WO2010059593A1 (en) * | 2008-11-18 | 2010-05-27 | Intellikine, Inc. | Methods and compositions for treatment of ophthalmic conditions |
WO2010068238A1 (en) * | 2008-12-10 | 2010-06-17 | Albert Einstein College Of Medicine Of Yeshiva University | Hypoxia targeted compounds for cancer diagnosis and therapy |
ES2552087T3 (es) | 2009-02-05 | 2015-11-25 | Tokai Pharmaceuticals, Inc. | Nuevos profármacos de inhibidores de CYP17 esteroidales/antiandrógenos |
WO2010123792A1 (en) | 2009-04-20 | 2010-10-28 | Osi Pharmaceuticals, Inc. | Preparation of c-pyrazine-methylamines |
EP2427192A1 (en) * | 2009-05-07 | 2012-03-14 | OSI Pharmaceuticals, LLC | Use of osi-906 for treating adrenocortical carcinoma |
WO2011011716A1 (en) * | 2009-07-23 | 2011-01-27 | The Trustees Of Princeton University | Inhibitors of mtor kinase as anti-viral agents |
SG10201404886PA (en) | 2009-08-17 | 2014-10-30 | Intellikine Llc | Heterocyclic compounds and uses thereof |
US20120220595A1 (en) | 2009-11-12 | 2012-08-30 | OSI Pharmaceuticals, LLC | Deuterated Tyrosine Kinase Inhibitors |
KR101661383B1 (ko) * | 2010-02-08 | 2016-09-29 | 머크 샤프 앤 도메 비.브이. | 8-메틸-1-페닐-이미다졸[1,5-a]피라진 화합물 |
US20130005733A1 (en) | 2010-03-09 | 2013-01-03 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
US20120028972A1 (en) * | 2010-07-30 | 2012-02-02 | Lilly Wong | Biomarker assays for detecting or measuring inhibition of tor kinase activity |
JP6130305B2 (ja) | 2011-02-23 | 2017-05-17 | インテリカイン, エルエルシー | キナーゼ阻害剤の組み合わせおよびそれらの使用 |
EP2548877A1 (en) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
MY192354A (en) | 2011-07-19 | 2022-08-17 | Merck Sharp & Dohme | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors |
WO2013152342A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Anti-cancer mtor inhibitor and anti-androgen combination |
CN104995192A (zh) * | 2012-09-26 | 2015-10-21 | 加利福尼亚大学董事会 | Ire1的调节 |
TW201441234A (zh) | 2013-01-23 | 2014-11-01 | Merck Sharp & Dohme | Btk抑制劑 |
WO2014113932A1 (en) * | 2013-01-23 | 2014-07-31 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2014113942A1 (en) | 2013-01-23 | 2014-07-31 | Merck Sharp & Dohme Corp. | Btk inhibitors |
CA2904170A1 (en) | 2013-03-14 | 2014-09-25 | University Of Maryland, Baltimore | Androgen receptor down-regulating agents and uses thereof |
JP6360881B2 (ja) | 2013-03-22 | 2018-07-18 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | 触媒的mtorc1/2阻害薬及びオーロラaキナーゼの選択的阻害薬の組合せ |
CN105636594A (zh) | 2013-08-12 | 2016-06-01 | 托凯药业股份有限公司 | 使用雄激素靶向疗法用于治疗肿瘤性疾病的生物标记物 |
AU2014358868A1 (en) | 2013-12-05 | 2016-06-09 | Acerta Pharma B.V. | Therapeutic combination of a PI3K inhibitor and a BTK inhibitor |
US9512092B2 (en) | 2013-12-12 | 2016-12-06 | Albert Einstein College Of Medicine, Inc. | Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof |
EP3082809B1 (en) | 2013-12-20 | 2021-01-20 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2015095102A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Btk inhibitors |
EP3094314B1 (en) | 2014-01-16 | 2021-06-23 | MUSC Foundation For Research Development | Targeted nanocarriers for the administration of immunosuppressive agents |
US10272083B2 (en) | 2014-01-21 | 2019-04-30 | Acerta Pharma B.V. | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
US10179135B2 (en) | 2014-01-24 | 2019-01-15 | Lam Therapeutics, Inc. | Apilimod compositions and methods for using same |
US9937171B2 (en) | 2014-04-11 | 2018-04-10 | Acerta Pharma B.V. | Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase |
TW201613644A (en) | 2014-06-17 | 2016-04-16 | Acerta Pharma Bv | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, and/or a JAK-2 inhibitor |
HRP20211813T1 (hr) | 2014-08-11 | 2022-03-04 | Acerta Pharma B.V. | Terapeutske kombinacije inhibitora btk i inhibitora bcl-2 |
ES2741399T3 (es) | 2014-11-07 | 2020-02-10 | Ai Therapeutics Inc | Apilimod para el uso en el tratamiento de cáncer renal |
WO2016106628A1 (en) * | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2016106624A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Tertiary alcohol imidazopyrazine btk inhibitors |
WO2016106623A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Benzamide imidazopyrazine btk inhibitors |
WO2016106629A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2016106626A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Imidazopyrazine analogs with 3-tertiary carbon substitutions as btk inhibitors |
WO2016106627A1 (en) * | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Btk inhibitors |
FR3037959B1 (fr) * | 2015-06-23 | 2017-08-04 | Servier Lab | Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
EP3613745B1 (en) | 2015-07-02 | 2021-09-01 | Acerta Pharma B.V. | Solid forms and formulations of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide |
WO2017024310A1 (en) | 2015-08-06 | 2017-02-09 | Chimerix, Inc. | Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents |
WO2017178844A1 (en) | 2016-04-15 | 2017-10-19 | Cancer Research Technology Limited | Heterocyclic compounds as ret kinase inhibitors |
PL3442535T3 (pl) | 2016-04-15 | 2022-10-24 | Cancer Research Technology Limited | Związki heterocykliczne jako inhibitory kinazy ret |
GB201705971D0 (en) | 2017-04-13 | 2017-05-31 | Cancer Res Tech Ltd | Inhibitor compounds |
EA202090103A1 (ru) | 2017-06-22 | 2020-04-24 | Селджин Корпорейшн | Лечение гепатоцеллюлярной карциномы, которая характеризуется вирусной инфекцией гепатита b |
CA3074139A1 (en) | 2017-09-01 | 2019-03-07 | Richard M. Keenan | Compounds and compositions for ire1 inhibition |
EP3684771A1 (en) | 2017-09-21 | 2020-07-29 | Chimerix, Inc. | MORPHIC FORMS OF 4-AMINO-7-(3,4-DIHYDROXY-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL)-2-METHYL-7H-PYRROLO[2,3-d]PYRIMIDINE-5-CARBOXAMIDE AND USES THEREOF |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5217999A (en) | 1987-12-24 | 1993-06-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Styryl compounds which inhibit EGF receptor protein tyrosine kinase |
ATE114661T1 (de) | 1990-04-02 | 1994-12-15 | Pfizer | Benzylphosphonsäure-tyrosinkinaseinhibitoren. |
US5302606A (en) | 1990-04-16 | 1994-04-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase |
US6645969B1 (en) | 1991-05-10 | 2003-11-11 | Aventis Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
ES2108120T3 (es) | 1991-05-10 | 1997-12-16 | Rhone Poulenc Rorer Int | Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf. |
EP0586608A1 (en) | 1991-05-29 | 1994-03-16 | Pfizer Inc. | Tricyclic polyhydroxylic tyrosine kinase inhibitors |
SK283413B6 (sk) | 1992-08-06 | 2003-07-01 | Warner-Lambert Company | 2-Tioindoly, 2-indolíntióny a polysulfidy, ich selénové analógy a farmaceutické prostriedky na ich báze |
MX9304801A (es) | 1992-08-06 | 1997-06-28 | Warner Lambert Co | 2-toindoles (selenoidoles) disulfuros (seleniduros) relacinados, los cuales inhiben a las proteinas tirosina cinasas y los cuales tienen propiedades anti-tumorales. |
GB9226855D0 (en) | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
JPH07133280A (ja) | 1993-11-09 | 1995-05-23 | Takeda Chem Ind Ltd | セフェム化合物、その製造法および抗菌組成物 |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
CH690773A5 (de) | 1996-02-01 | 2001-01-15 | Novartis Ag | Pyrrolo(2,3-d)pyrimide und ihre Verwendung. |
US6514971B1 (en) | 1996-03-15 | 2003-02-04 | Zeneca Limited | Cinnoline derivatives and use as medicine |
US6232299B1 (en) | 1996-05-01 | 2001-05-15 | Eli Lilly And Company | Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy |
UA54427C2 (uk) | 1996-05-01 | 2003-03-17 | Елі Ліллі Енд Компані | Спосіб лікування очних захворювань, які пов'язані з фактором васкулярного ендотеліального росту |
WO1997040830A1 (en) | 1996-05-01 | 1997-11-06 | Eli Lilly And Company | Therapeutic treatment for vegf related diseases |
GB9707800D0 (en) | 1996-05-06 | 1997-06-04 | Zeneca Ltd | Chemical compounds |
US6713474B2 (en) | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
KR20010085824A (ko) | 1998-09-18 | 2001-09-07 | 스타르크, 카르크 | 단백질 키나아제 억제제로서의 피롤로피리미딘 |
US6337338B1 (en) | 1998-12-15 | 2002-01-08 | Telik, Inc. | Heteroaryl-aryl ureas as IGF-1 receptor antagonists |
US6982265B1 (en) | 1999-05-21 | 2006-01-03 | Bristol Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
DK1183033T3 (da) | 1999-05-21 | 2006-06-06 | Bristol Myers Squibb Co | Pyrrolotriazininhibitorer af kinaser |
WO2001072751A1 (en) | 2000-03-29 | 2001-10-04 | Knoll Gesellschaft Mit Beschraenkter Haftung | Pyrrolopyrimidines as tyrosine kinase inhibitors |
AR035885A1 (es) | 2001-05-14 | 2004-07-21 | Novartis Ag | Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica |
SE0102168D0 (sv) | 2001-06-19 | 2001-06-19 | Karolinska Innovations Ab | New use and new compounds |
US6939874B2 (en) | 2001-08-22 | 2005-09-06 | Amgen Inc. | Substituted pyrimidinyl derivatives and methods of use |
US7115617B2 (en) | 2001-08-22 | 2006-10-03 | Amgen Inc. | Amino-substituted pyrimidinyl derivatives and methods of use |
ATE420879T1 (de) | 2001-09-19 | 2009-01-15 | Aventis Pharma Sa | Indolizine als kinaseproteinhemmer |
GB0122560D0 (en) | 2001-09-19 | 2001-11-07 | Aventis Pharma Ltd | Chemical compounds |
SE0104140D0 (sv) | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
EP1476192B1 (en) | 2002-02-14 | 2007-04-25 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for treating hyperproliferative conditions |
US20050215564A1 (en) | 2002-02-14 | 2005-09-29 | Stiles Charles D | Methods and compositions for treating hyperproliferative conditions |
US7186832B2 (en) * | 2003-02-20 | 2007-03-06 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
JP2005089352A (ja) * | 2003-09-16 | 2005-04-07 | Kissei Pharmaceut Co Ltd | 新規なイミダゾ[1,5−a]ピラジン誘導体、それを含有する医薬組成物およびそれらの用途 |
AU2004282219C1 (en) | 2003-10-15 | 2009-12-17 | Osi Pharmaceuticals, Inc. | Imidazo [1, 5 - a] pyrazine tyrosine kinase inhibitors |
PT1740591E (pt) * | 2004-04-02 | 2009-09-24 | Osi Pharm Inc | Inibidores da proteína quinase heterobicíclicos em substituição de anel bicíclico 6,6 |
JP5335432B2 (ja) * | 2005-11-17 | 2013-11-06 | オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー | 縮合2環系mTOR阻害剤 |
-
2006
- 2006-12-01 AR ARP060105328A patent/AR057960A1/es not_active Application Discontinuation
- 2006-12-04 WO PCT/US2006/046226 patent/WO2007064993A2/en active Application Filing
- 2006-12-04 ES ES06844779T patent/ES2395835T3/es active Active
- 2006-12-04 US US11/633,301 patent/US7648987B2/en not_active Expired - Fee Related
- 2006-12-04 TW TW095145016A patent/TW200730528A/zh unknown
- 2006-12-04 EP EP06844779A patent/EP1957496B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
TW200730528A (en) | 2007-08-16 |
US7648987B2 (en) | 2010-01-19 |
EP1957496B1 (en) | 2012-10-24 |
ES2395835T3 (es) | 2013-02-15 |
WO2007064993A3 (en) | 2007-07-26 |
EP1957496A2 (en) | 2008-08-20 |
US20070149521A1 (en) | 2007-06-28 |
WO2007064993A2 (en) | 2007-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR057960A1 (es) | Inhibidores de proteina quinasa biciclicos | |
PE20151951A1 (es) | Heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b | |
DOP2020000083A (es) | Compuesto de pirimidina como inhibidor de las janocinasas | |
CL2019003188A1 (es) | Sales de inhibidor de pi3k y procesos de preparación. (divisional solicitud 201702179) | |
AR103222A1 (es) | Procedimiento para la preparación de análogos de 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidina | |
SV2016005229A (es) | Inhibidores de syk | |
UY33337A (es) | DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS | |
CO2018011408A2 (es) | Compuestos de pirimidina como inhibidores de la quinasa jak | |
AR073818A1 (es) | Imidazopiridazinacarbonitrilos utiles como inhibidores de quinasa | |
DOP2013000277A (es) | 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina | |
CR9146A (es) | Sal potasica de un inhibidor de la integrasa de vih | |
AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
ECSP10010019A (es) | Proceso para la producir derivados de piripiropeno e intermediarios para la producción de los mismos | |
UY35139A (es) | 4- (orto) -fluorofenil-5-fluoropirimidin-2-ilaminas que contienen un grupo sulfoximina | |
AR100806A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
ECSP18026386A (es) | Sales de un inhibidor de pim quinasa | |
AR077215A1 (es) | Derivados de piperidina, composiciones farmaceuticas y metodos relacionados con ellos | |
CO2019004978A2 (es) | Compuestos terapéuticos y métodos para utilizarlos | |
BR112018073488A2 (pt) | intermediários para a síntese de derivados de ácido biliar, em particular de ácido obeticólico | |
UY33270A (es) | Sales cristalinas de un potente inhibidor del hcv | |
CL2015001319A1 (es) | Compuestos derivados de n-(piridin-2-il)pirimidin-4-amina que contienen un grupo sulfoximina; compuestos intermediarios; composicion farmaceutica; combinacion farmaceutica; y metodo para la preparacion de compuestos. | |
CO2019001181A2 (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2 | |
CO2017008809A2 (es) | Compuestos de benzoxaborol y uso de los mismos | |
BR112016013618A8 (pt) | derivados de maleimida como moduladores de série de reação de wnt, seus usos, composição farmacêutica e processo para a preparação dos mesmos | |
AR099893A1 (es) | Uso de compuestos heterocíclicos para controlar nematodos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |